• Achilles Therapeutics

    Achilles Therapeutics

    Achilles Therapeutics is focused on the development of novel cancer immuno therapiestargeting truncal tumour neo-antigens, and brings together world-class research from UCL (University College London) and the Francis Crick Institute, funded by Cancer Research UK and the National Institute for Health Research (NIHR).Truncal tumour neo-antigens are unique flags to the immune system present on all cancer cells in an individual patient’s tumour but not on healthy cells, allowing scientists read more...

  • AKL Research & Development Ltd

    AKL Research & Development Ltd

    AKL Research & Development Ltd.'s focus is primarily inflammatory diseases, particularly those related to dysregulation of the innate immune system. AKL RD identifies secondary metabolites of plant origin with proven efficacy and safety. These metabolites are then synthesized before undergoing standard pharmaceutical clinical development. This innovative approach greatly increases the chances of success, while reducing the probability of unexpected side effects. This has resulted in read more...

  • Antikor                       


    Antikor Biopharma Ltd is developing the next-generation of ADCs (antibody drug conjugates) based on optimising antibody fragments through its OptiLink technology. Our multi-disciplinary team of synthetic chemists, antibody engineers, bioconjugation experts and assay scientists cover the full spectrum of payload synthesis to ADC testing to discover high efficacious cancer therapeutics with a high therapeutic index. Collaborations and partnering enquiries are encouraged. read more...

  • Apollo Therapeutics

    Apollo Therapeutics

    Apollo Therapeutics is a unique collaboration between three global pharmaceutical companies (GSK, J&J and AZ) and the technology transfer offices of Imperial College London, University College London and the University of Cambridge. This is the first time that three global pharmaceutical companies and the tech transfer offices of three world leading universities has come together to form a joint enterprise resulting in a truly innovative venture. Apollo will support translational research, read more...

  • Autifony Therapeutics

    Autifony Therapeutics

    Autifony Therapeutics aims to develop new drugs to treat hearing disorders using pioneering science. Hearing disorders affect a significant proportion of the population, and while devices such as hearing aids and cochlear implants can ease the problems for some, many people suffer silently. As well as causing social isolation and distress, hearing loss also brings with it a considerable economic cost to society, with increased risk of unemployment, the need for carer support, and other read more...

  • Cyclogenix


    Cyclogenix is a UK-based biotech focused on the development of novel biotherapeutics with wide-ranging expertise in cyclotide-based drug delivery systems and antibody engineering. Having successfully attracted funding from large Pharmaceutical companies, venture groups and public agencies, our main interests for research and development currently are: Biotherapeutic Delivery Blood-brain Barrier Multispecific Cyclobodies Antibody Engineering

  • Freeline


    Freeline’s mission is to become a leading biopharmaceutical company founded on the successful development and commercialisation of liver directed gene therapies for bleeding disorders and other severe diseases. These therapies are based on our next-generation proprietary AAV vector platform, with our lead programme being a gene therapy to treat haemophilia B. This gene therapy treatment, pioneered by Professor Amit Nathwani, Professor of Haematology at UCL and CSO of Freeline read more...

  • Gyroscope Therapeutics

    Gyroscope Therapeutics

    Gyroscope Therapeutics Ltd is a private company founded by Syncona and Cambridge Enterprise and supported by its scientific founders with expertise in ophthalmology, immunology and gene therapy. Our mission is to develop genetically-defined therapies for the treatment of eye diseases linked to an unbalanced complement system. Our management and scientific teams have extensive experience in gene therapy and drug development, particularly in the field of ophthalmology, and have served read more...

  • Immune Regulation

    Immune Regulation

    Immune Regulation is a clinical stage biotech company, pioneering new technologies for resetting the immune system, developing first-in-class therapies for inflammatory and immunological diseases. Our visionary approach aims to transform patients’ lives for the better. Immune Regulation is at the leading edge in the field of developing novel immuno modulatory platforms to address unmet clinical needs, initially in the significant respiratory and rheumatoid arthritis markets as well as read more...

  • KaNDy Therapeutics

    KaNDy Therapeutics

    KaNDy Therapeutics is a clinical-stage company focused on optimising the potential of NT-814 in the treatment of common, chronic debilitating female sex-hormone related conditions, with an initial focus on symptoms of the menopause. KaNDy Therapeutics was spun out from NeRRe Therapeutics, itself a spin out from GSK, in 2017 at which time all data and intellectual property associated with NT-814 was transferred to KaNDy Therapeutics.

  • LifeArc


    LifeArc is the new name for MRC Technology, a medical research charity with a 25 year legacy of helping scientists and organisations turn their research into treatments and diagnostics for patients. The charity is pioneering new ways to turn great science into greater patient impact. It has dedicated laboratories in Stevenage where around 80 scientists work on antibody and small molecule projects, while the Edinburgh lab progresses diagnostics development.

  • Lift Biosciences

    Lift Biosciences

    LIfT BioSciences is a socially-minded Biotech start-up developing The World's First Cell Bank of Cancer Killing Granulocytes (a type of white blood cell). The Cell Bank will enable us to provide a range of potentially life-saving immuno-oncology cell therapies for different solid tumour types. Our innate immunity platform is known as Leukocyte Infusion Therapy (LIfT). LIfT BioSciences Ltd was set-up with Prof Zhen Cui of Wake Forest University, a leading pioneer in LIFT, following his read more...

  • NeRRe Therapeutics

    NeRRe Therapeutics

    NeRRe Therapeutics is a UK based, mid-stage clinical company that has a unique tachykinin portfolio of 4 neurokinin (NK) antagonists: three NK-1 antagonists and a dual mechanism NK-1, 3 antagonist. The company is closing a Series B round of funding to support the continued clinical development of both lead assets: 1. NK-1 antagonist Orvepitant for the treatment of Chronic Refractory Cough 2. Dual mechanism NK-1, 3 antagonist NT-814 for the treatment of moderate to read more...

  • Ossianix


    Ossianix is a drug discovery & development company that utilises natural single domain antibodies called VNARs. These compact antigen - binding domain have long , finger like projections that preferentially seek out buried binding pockets and active sites that are typically inaccessible to conventional monoclonal antibodies. VNARs can be readily formatted to produce mono, bi & tri -specific antibodies and Ossianix is developing a product pipeline to targets in inflammation, read more...

  • Plasticell


    Plasticell specialises in the differentiation of stem cells to generate hard-to-obtain human cell types for drug discovery and therapeutic (ATMP) applications. Plasticell’s proprietary, award-winning Combination Cell Culture (CombiCult®) platform technology, is a bead-based combinatorial screening method developed especially for use in stem cell research. Plasticell is developing a number of hematopoietic cell therapies, with the lead programme being the expansion of read more...

  • Progenitor Therapeutics

    Progenitor Therapeutics

    Progenitor is a pioneering regenerative medicine company that develops small molecule drugs to regenerate specific tissues of the human body in response to injury, disease or aging. The drugs stimulate the body’s innate regeneration machinery to cure disease, rather than simply treating the symptoms of illness. We are focusing initially on three therapeutic programmes, to address serious conditions that affect millions of patients worldwide.

  • Reviral


    ReViral is a UK-based biotechnology company with a portfolio of drugs to treat Respiratory Syncytial Virus (RSV) infection. RSV currently represents a major unmet medical need in children, the elderly and the immuno compromised. Our most advanced programme, RV521, is a highly potent, orally-administered inhibitor of RSV fusion protein, and has demonstrated top-line safety and pharmacokinetic data in Phase1 single and multiple ascending dose (SAD and MAD) trials. RV521 has successfully read more...

  • University College London

    University College London

    University College London in partnership with National institute for Health Research (NIHR) University College London Hospitals Biomedical Research Centre has located translational research projects and spin-outs at its laboratories in SBC. These projects have high commercialization potential and cover a broad range of technologies in drug discovery and medical devices. UCL is driven to engage more closely with the biotechnology and pharmaceutical industries in SBC’s open innovation read more...

Dr Andrew Lightfoot
CEO and Board Director

"Peptinnovate's success has been underpinned by the pioneering interactions with GSK in which high quality data has supported large investment into Peptinnovate from overseas".

Funding Partners: